Related references
Note: Only part of the references are listed.The Rise of Molecular Glues
Stuart L. Schreiber
CELL (2021)
Development of a Hematopoietic Prostaglandin D Synthase-Degradation Inducer
Hidetomo Yokoo et al.
ACS MEDICINAL CHEMISTRY LETTERS (2021)
Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta
Nan Bai et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2021)
Duchenne muscular dystrophy
Dongsheng Duan et al.
NATURE REVIEWS DISEASE PRIMERS (2021)
Innovative Therapeutic Approaches for Duchenne Muscular Dystrophy
Fernanda Fortunato et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Degradation of proteins by PROTACs and other strategies
Yang Wang et al.
ACTA PHARMACEUTICA SINICA B (2020)
Design, Synthesis, and Evaluation of Highly Potent FAK-Targeting PROTACs
Hongying Gao et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Structure-Based Design of a Macrocyclic PROTAC
Andrea Testa et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2020)
Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
George M. Burslem et al.
CELL (2020)
Early phase 2 trial of TAS-205 in patients with Duchenne muscular dystrophy
Hirofumi Komaki et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2020)
PRosettaC: Rosetta Based Modeling of PROTAC Mediated Ternary Complexes
Daniel Zaidman et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2020)
Improved Accuracy for Modeling PROTAC-Mediated Ternary Complex Formation and Targeted Protein Degradation via New In Silico Methodologies
Michael L. Drummond et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2020)
ARID2 is a pomalidomide-dependent CRL4CRBN substrate in multiple myeloma cells
Junichi Yamamoto et al.
NATURE CHEMICAL BIOLOGY (2020)
In Silico Modeling of PROTAC-Mediated Ternary Complexes: Validation and Application
Michael L. Drummond et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2019)
Therapeutic Potential of Hematopoietic Prostaglandin D2 Synthase in Allergic Inflammation
Sonja Rittchen et al.
CELLS (2019)
Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection
David A. DeGoey et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds
Kwok-Ho Chan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Plasticity in binding confers selectivity in ligand-induced protein degradation
Radoslaw P. Nowak et al.
NATURE CHEMICAL BIOLOGY (2018)
Homo-PROTACs for the Chemical Knockdown of Cereblon
Christian Steinebach et al.
ACS CHEMICAL BIOLOGY (2018)
Characterization of crystal water molecules in a high-affinity inhibitor and hematopoietic prostaglandin D synthase complex by interaction energy studies
Daisuke Takaya et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
A phase I study of TAS-205 in patients with Duchenne muscular dystrophy
Eri Takeshita et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2018)
Induced protein degradation: an emerging drug discovery paradigm
Ashton C. Lai et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Structural basis of PROTAC cooperative recognition for selective protein degradation
Morgan S. Gadd et al.
NATURE CHEMICAL BIOLOGY (2017)
A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase
Mary E. Matyskiela et al.
NATURE (2016)
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
Kanak Raina et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Lenalidomide induces ubiquitination and degradation of CK1a in del(5q) MDS
Jan Kroenke et al.
NATURE (2015)
Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN
Anita K. Gandhi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
Bradley Croy Doak et al.
CHEMISTRY & BIOLOGY (2014)
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Jan Kroenke et al.
SCIENCE (2014)
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Gang Lu et al.
SCIENCE (2014)
A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old
Taku Nakagawa et al.
CLINICA CHIMICA ACTA (2013)
Recent reports about enzymes related to the synthesis of prostaglandin (PG) F2 (PGF2α and 9α, 11β-PGF2)
Kikuko Watanabe
JOURNAL OF BIOCHEMISTRY (2011)
Prostaglandin E synthases: Understanding their pathophysiological roles through mouse genetic models
Shuntaro Hara et al.
BIOCHIMIE (2010)
Inhibition of Prostaglandin D Synthase Suppresses Muscular Necrosis
Ikuko Mohri et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Prostaglandin F2 Synthase Activities of AldoKeto Reductase 1B1, 1B3 and 1B7
Zakayi Kabututu et al.
JOURNAL OF BIOCHEMISTRY (2009)
Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: A comparative study from the Pediatric Cardiomyopathy Registry
David M. Connuck et al.
AMERICAN HEART JOURNAL (2008)
Hematopoietic prostaglandin D synthase is expressed in microglia in the developing postnatal mouse brain
I Mohri et al.
GLIA (2003)
Induction of hematopoietic prostaglandin D synthase in hyalinated necrotic muscle fibers: its implication in grouped necrosis
T Okinaga et al.
ACTA NEUROPATHOLOGICA (2002)
Molecular properties that influence the oral bioavailability of drug candidates
DF Veber et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
Prostaglandin D2 as a mediator of allergic asthma
T Matsuoka et al.
SCIENCE (2000)
Share Paper
